Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain, brain stem and spinal cord that control voluntary muscle movement.
ALS is also known as Lou Gehrig disease.
Alternative Names
Lou Gehrig disease; ALS; Upper and lower motor neuron disease; Motor neuron disease
Causes
One in 10 cases of ALS is due to a genetic defect. The cause is unknown in most other cases.
In ALS, motor nerve cells (neurons) waste away or die, and can no longer send messages to muscles. This eventually leads to muscle weakening, twitching, and an inability to move the arms, legs, and body. The condition slowly gets worse. When the muscles in the chest area stop working, it becomes hard or impossible to breathe.
ALS affects approximately 5 out of every 100,000 people worldwide.
Having a family member who has a hereditary form of the disease is a risk factor for ALS. Other risks include military service. The reasons for this are unclear, but it may have to do with environmental exposure to toxins.
Symptoms
Symptoms usually do not develop until after age 50, but they can start in younger people. People with ALS have a loss of muscle strength and coordination that eventually gets worse and makes it impossible for them to do routine tasks such as going up steps, getting out of a chair, or swallowing.
Weakness can first affect the arms or legs, or the ability to breathe or swallow. As the disease gets worse, more muscle groups develop problems.
ALS does not affect the senses (sight, smell, taste, hearing, touch). Most people are able to think normally, although a small number develop dementia, causing problems with memory.
Muscle weakness starts in one body part, such as the arm or hand, and slowly gets worse until it leads to the following:
Difficulty lifting, climbing stairs, and walking
Difficulty breathing
Difficulty swallowing -- choking easily, drooling, or gagging
Head drop due to weakness of the neck muscles
Speech problems, such as a slow or abnormal speech pattern (slurring of words)
There is no known cure for ALS. Two medicines are available that help slow the progression of symptoms and may help people live slightly longer:
Riluzole (Rilutek)
Edaravone (Radicava)
Treatments to control other symptoms include:
Baclofen or diazepam for spasticity that interferes with daily activities
Trihexyphenidyl or amitriptyline for people with problems swallowing their own saliva
Physical therapy, rehabilitation, use of braces or a wheelchair, or other measures may be needed to help with muscle function and general health.
People with ALS tend to lose weight. The illness itself increases the need for food and calories. At the same time, problems with choking and swallowing make it hard to eat enough. To help with feeding, a tube may be placed into the stomach. A dietitian who specializes in ALS can give advice on healthy eating.
Breathing devices include machines that are used only at night, and constant mechanical ventilation.
Medicine for depression may be needed if a person with ALS is feeling sad. They also should discuss their wishes regarding artificial ventilation with their families and providers.
Support Groups
Emotional support is vital in coping with the disorder, because mental functioning is not affected. Groups such as the ALS Association may be available to help people who are coping with the disorder.
Support for people who are caring for someone with ALS is also available, and may be very helpful.
Outlook (Prognosis)
Over time, people with ALS lose the ability to function and care for themselves. Death often occurs within 3 to 5 years of diagnosis. About 1 in 4 people survive for more than 5 years after diagnosis. Some people live much longer, but they typically need help breathing from a ventilator or other device.
Fearon C, Murray B, Mitsumoto H. Disorders of upper and lower motor neurons. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 97.
Shaw PJ, Cudkowicz ME. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 391.
van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098. PMID: 28552366 .
Last reviewed June 13, 2024 by Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team..
BOB体育 research scientists make medicine better every day. They discover new ways to help
people by running clinical trials. When you join a clinical trial, you can get advanced
medical care. Sometimes years before it's available everywhere. You can also help make
medicine better for everyone else.
If you'd like to learn more about clinical trials, visit our
clinical trials page. Or click one of the links below:
The purpose of this research study is to determine the effects of a medication, istradefylline, in conjunction with breathing air with reduced oxygen for short periods of time (called acute intermittent hypoxia, or AIH), on breathing. This project鈥�
Investigator
May Smith-Hublou
Status
Accepting Candidates
Ages
21 Years - 80 Years
Sexes
All
News and Patient Stories: Amyotrophic lateral sclerosis (ALS)
Matthew D. Disney, Ph.D., a professor and chair of the Department of Chemistry at The Wertheim UF Scripps Institute for Biomedical Innovation & Technology, has鈥�